The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study)
Sergio Cortelazzo(Azienda Ospedaliero-Universitaria delle Marche), Emanuele Zucca(Università della Svizzera italiana), Silvia Rudoy, Robert Blum(Universitätsklinikum Würzburg), Andrea Rossi(Fondazione Toscana Gabriele Monasterio), Felice Pasini(Ospedale Civile Di Ivrea), Maria Cantonetti(University of Rome Tor Vergata), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Michael Mian(Ospedale di Bolzano), Osnat Bairey(Tel Aviv University), Giovanni Martinelli(University of Bologna), Emilio Berti(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Liliana Devizzi(Fondazione IRCCS Istituto Nazionale dei Tumori), M Busetto(Ospedali Riuniti Umberto I), Achille Ambrosetti(International Extranodal Lymphoma Study Group), Andrés JM Ferreri, Enrico Pogliani(Azienda Ospedaliera San Gerardo), Andreas H. Sarris(Hygeia Hospital), Richard Tsang(University of Toronto), Graziella Pinotti(Medica (Italy)), Giuseppe Lombardo(Vision Engineering (Italy))
Cited by 0
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k